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THE STUDY
Study addresses a very important question relevant to therapeutics, particularly in LMICs. The evaluation form provided is not entirely appropriate to a manuscript of this type, a systematic review of the literature. Because of the nature of the question asked, the authors are forced to rely on a literature base of limited quality with almost all relevant studies conducted in LMICs.
The main outcome measure is not entirely clear because the authors have chosen to combine reports re counterfeit and substandard medicines in a single review. This is understandable because most published literature refers to substandard rather than counterfeit medicines, although counterfeit products are the major concern.
The abstract/summary/key messages/limitations are reasonably complete but the message about limitations related to sampling methods is not clear from the abstract. The abstract is quite repetitive in describing the absence of data from upper middle income and high income countries. This is repeated three times in the abstract although this observation is of limited interest compared to the description of the situation in LMICs.
In the results section of the abstract, the opening statement is not a sentence.
Statistical methods are not described because they are generally not appropriate to a study of this kind.
The standard of English is acceptable but the manuscript requires careful review for grammar. In some places the manuscript is confusing because the authors have referred to prevalence without specifying "prevalence of substandard or counterfeit medicines".
While the references are up to date, they are sometimes described in cursory fashion and should be checked carefully. This is particularly true of the frequent references to WHO reports (eg, references 22, 23, 26) . Many of the references have not been accessed for one or two years.
There are no supplemental documents.
RESULTS & CONCLUSIONS
The results from the systematic literature review are relatively clear but the presentation is somewhat circumlocutory and the volume of text could probably be reduced by at least 30% to improve the manuscript"s impact. The information is described in the text then presented in greater detail in a series of 9 tables. The main message of the manuscript will be clearer if some of these tables are omitted or their results presented only in the text. Perhaps the authors could select key emssages to be conveyed in the table.
REPORTING & ETHICS
A study of this kind does not require ethical review and consequently no issues are identified.
GENERAL COMMENTS
Supplementary comments:
• Abstract -strengths & limitations: The intent of the second bullet comment is unclear and it should be reworded.
• Introduction, line 4: "Even low priced medicines simply taken to relieve pain are vulnerable to counterfeiting." The meaning of this sentence is unclear and it should be rewritten.
• page 4, lines 19-20: The statement of objective is "to explore and summarize the magnitude and extent of the problem of counterfeit and substandard medicines". The combination of these two concerns will create some confusion for readers. It is clear that substandard production of medicines is much more common in the reports cited than is actual counterfeiting. The complete absence of active medication obviously has greater clinical implications.
• page 6, statistical analysis: "The median prevalence of these drugs was analyzed for each income level group." In this and several other places, prevalence is used with a clear implication that it is the prevalence of substandard and counterfeit medicines that is being described, but this needs to be explicit.
• The discussion of the limitation encountered in drawing conclusions concerning counterfeiting is inadequate. Perhaps this specific limitation could be more fully described by the authors.
• The discussion of pediatric formulations is based on two studies reporting on syrup/suspension formulations of antimalarials. This is an important area of concern in LMICs but the information found by the authors is inadequate to support inclusion in this paper or in the fuller discussion presented on page 9.
• The statement at the end of the discussion (page 10) that "there are a number of national and international initiatives taking place led by WHO and it member states working group" is very weak. 
REVIEWER

GENERAL COMMENTS
Thank you for the opportunity to review this manuscript that attempts to conduct a systematic review of counterfeit/falsified/substandard medicine prevalence studies to establish some indication of the extent of this global health problem.
Specific comments ============= 1. Abstract: I would rephrase the objective here. Clearly, there is no way to establish the extent of the global counterfeit problem simply by reviewing the current literature available as this literature may only represent one component of counterfeit (for a lack of a better term) medicines reporting. Indeed, the sample from the literature is not even representative of the problem and the complex issues regarding adequate surveillance and reporting make this objective basically impossible to achieve currently. Please rephrase appropriately to note these limitations. The conclusion statement should also be rewritten to acknowledge these limitations. This is only a subset of medicines that have been reviewed, so it should be acknowledged that based on the systematic review conducted, there appears to be a high-prevalence of counterfeit medicines for certain therapeutic classes in countries where studies were conducted. Something along those lines. I know this is mentioned in your strengths and limitations, but also needs to be reflected in these statements. 2. Introduction: First paragraph really needs to flush out the issue better. There is a huge diversity of counterfeited medicines and any medicine that is counterfeit has the potential to harm patients, regardless if it is a life-saving drug, lifestyle drug, etc. Any of these drugs has the potential for substandard or toxic contents. Also, counterfeit medicines such as the Avastin case in the USA have been detected, so this is not just an LMIC/LIC problem, though prevalence is arguably higher in these settings. (29) and their criteria score would be very helpful. For example, a study recently published in BMJ Open that was in the review period seems to meet a number of the criteria required for inclusion (see: http://bmjopen.bmj.com/content/2/3/e000854.full) I would like to know why some of these studies were excluded based on their criteria scores. Overall, this is an extremely important topic and a systematic review of prevalence in the literature is sorely needed. That said, the authors need to improve the manuscript based on the comments presented and really narrow the discussion and conclusions to the limitations of the review. Reviewer"s comment #1: Study addresses a very important question relevant to therapeutics, particularly in LMICs. The evaluation form provided is not entirely appropriate to a manuscript of this type, a systematic review of the literature. Because of the nature of the question asked, the authors are forced to rely on a literature base of limited quality with almost all relevant studies conducted in LMICs.
VERSION 1 -AUTHOR RESPONSE
Authors" response: Thank you very much for your valuable comments .The main outcome is to report the prevalence of counterfeit and substandard medicines reported by these studies. The majority of these studies were conducted to evaluate the quality of medicines. Only two studies took the analysis further to investigate the authenticity of these drugs and worked out the prevalence of counterfeit drugs. Therefore, it was difficult to work out the prevalence for each problem. Thus, we decided to combine the two terms as both are medicines with poor quality and can be harmful to patients.
Reviewer"s comment #2: The abstract/summary/key messages/limitations are reasonably complete but the message about limitations related to sampling methods is not clear from the abstract.
Authors" response: Limitations of the review are now added into the abstract (please see abstract page no. 2)
Reviewer"s comment #3: The abstract is quite repetitive in describing the absence of data from upper middle income and high income countries. This is repeated three times in the abstract although this observation is of limited interest compared to the description of the situation in LMICs.
Authors" response: We deleted the repetition from the abstract. (Please see abstract page no. 2)
Reviewer"s comment #4: In the results section of the abstract, the opening statement is not a sentence.
Authors" response: The opening statement of the result is rewritten. (Please see abstract page no. 2)
Reviewer"s comment #5: The standard of English is acceptable but the manuscript requires careful review for grammar.
Authors" response: We have reviewed the paper and corrected the grammar where appropriate.
Reviewer"s comment #6: In some places the manuscript is confusing because the authors have referred to prevalence without specifying "prevalence of substandard or counterfeit medicines".
Authors" response: We have clarified this in the method section (page no. 6). We have also added another heading to the result section to discuss the prevalence of counterfeit medicines that has been worked out by studies that conducted packaging analysis (page no. 8)
Reviewer"s comment #7: While the references are up to date, they are sometimes described in cursory fashion and should be checked carefully. This is particularly true of the frequent references to WHO reports (eg, references 22, 23, 26). Many of the references have not been accessed for one or two years.
Authors" response: We have updated the references.
Reviewer"s comment #8: The results from the systematic literature review are relatively clear but the presentation is somewhat circumlocutory and the volume of text could probably be reduced by at least 30% to improve the manuscript's impact.
Authors" response: We have tried to summarise the results and decrease the volume of text.
Reviewer"s comment #9: The information is described in the text then presented in greater detail in a series of 9 tables. The main message of the manuscript will be clearer if some of these tables are omitted or their results presented only in the text. Perhaps the authors could select key messages to be conveyed in the table.
Authors" response: The article now contains 3 tables with more details in the text. Extra data is available as supplementary online data.
Supplementary comments: Reviewer"s comment #10: Abstract -strengths & limitations: The intent of the second bullet comment is unclear and it should be reworded.
Authors" response: The second point of the strength and limitations is reworded. Please see page no.
Reviewer"s comment #11: Introduction, line 4: "Even low priced medicines simply taken to relieve pain are vulnerable to counterfeiting." The meaning of this sentence is unclear and it should be rewritten.
Authors" response: We have deleted the sentence and we have rewritten the first paragraph in the introduction. Please see page no.4
Reviewer"s comment #12: Page 4, lines 19-20: The statement of objective is "to explore and summarize the magnitude and extent of the problem of counterfeit and substandard medicines". The combination of these two concerns will create some confusion for readers. It is clear that substandard production of medicines is much more common in the reports cited than is actual counterfeiting. The complete absence of active medication obviously has greater clinical implications.
Authors" response: Please look at our response to the point no. 1and 6
Reviewer"s comment #13: Page 6, statistical analysis: "The median prevalence of these drugs was analyzed for each income level group." In this and several other places, prevalence is used with a clear implication that it is the prevalence of substandard and counterfeit medicines that is being described, but this needs to be explicit.
Authors" response: Please see explanation given above on clarification of the terms used.
Reviewer"s comment #14: The discussion of the limitation encountered in drawing conclusions concerning counterfeiting is inadequate. Perhaps this specific limitation could be more fully described by the authors.
Authors" response: These limitations are now discussed in the first paragraph of the discussion (page 9) and in the limitation section (page 11).
Reviewer"s comment #15: The discussion of pediatric formulations is based on two studies reporting on syrup/suspension formulations of antimalarials. This is an important area of concern in LMICs but the information found by the authors is inadequate to support inclusion in this paper or in the fuller discussion presented on page 9.
Authors" response: As you have suggested, we have deleted table 4 and result section on paediatric formulations. We have also deleted the discussion on this area.
Reviewer"s comment #16: The statement at the end of the discussion (page 10) that "there are a number of national and international initiatives taking place led by WHO and it member states working group" is very weak.
Authors" response: We have strengthened this statement by adding other recent relevant initiatives going on to combat the problem. Please see the last paragraph of the discussion on page no. 10-11.
Reviewer: Yves Roggo F. Hoffmann-La Roche Ltd
Reviewer"s comment #1: I am not sur that the authors are using an adequate selection of the studies. I believe that there is a bias in the methodology. 15 papers have been selected out of 2363 only.
-A large impact is give to the who publications (4 papers /15).
-2 papers from one journal (trop Med Int Healt). No clear conclusion in this paper. Large description of the methodology but only few conclusions Authors" response: Thanks for your comments. It is usual to have a large number of papers at the beginning of a systematic review and therefore the numbers to be significantly reduced once the inclusion/exclusion criteria and quality assessment takes place. WHO publications make up a large number of papers as they have strong methodology, and are active in the regions studied. The journals were not preselected and all searched.
We have now strengthened the conclusions in the paper.
Reviewer Reviewer"s comment #1: Abstract: I would rephrase the objective here. Clearly, there is no way to establish the extent of the global counterfeit problem simply by reviewing the current literature available as this literature may only represent one component of counterfeit (for a lack of a better term) medicines reporting. Indeed, the sample from the literature is not even representative of the problem and the complex issues regarding adequate surveillance and reporting make this objective basically impossible to achieve currently. Please rephrase appropriately to note these limitations.
Authors" response: Thank you so much for reviewing of our manuscript and your valuable comments. The objective of the review is rephrased according to the above suggestion. Please see page no. 2
Reviewer"s comment #2: The conclusion statement should also be rewritten to acknowledge these limitations. This is only a subset of medicines that have been reviewed, so it should be acknowledged that based on the systematic review conducted, there appears to be a high-prevalence of counterfeit medicines for certain therapeutic classes in countries where studies were conducted. Something along those lines. I know this is mentioned in your strengths and limitations, but also needs to be reflected in these statements.
Authors" response: The conclusion is rewritten to highlight that the evidence is only for antimicrobial medicines as follows "The prevalence of poor quality antimicrobial medicines is widespread throughout Africa and Asia in LIC and LMIC. Inadequate amount of the active ingredients was the main problem identified"
Reviewer"s comment #3: Introduction: First paragraph really needs to flush out the issue better. There is a huge diversity of counterfeited medicines and any medicine that is counterfeit has the potential to harm patients, regardless if it is a life-saving drug, lifestyle drug, etc. Any of these drugs has the potential for substandard or toxic contents. Also, counterfeit medicines such as the Avastin case in the USA have been detected, so this is not just an LMIC/LIC problem, though prevalence is arguably higher in these settings. 
